NCT00291538已完成1 期
Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 6
- 主要终点
- characterize the pharmacokinetics of the 2 routes of administration.
研究概览
简要总结
In this open-label randomised phase I trial, bortezomib will be administrated to 2 groups of 10 patients with MM who have inclusion criteria use the extended 2nd line indication, either intravenously (group 1 = 10 patients) or subcutaneously (group 2 = 10 patients). The schedule of administration of bortezomib will be the following : 1.3 mg per square meter of body-surface area twice weekly for 2 weeks, followed by 1 week without treatment, for up to eight cycles, either IV (group 1) or SC (group 2).
The primary objective is to characterize the pharmacokinetics of the 2 routes of administration.
The secondary objectives are to characterize the pharmacodynamics (20S proteasome inhibition in whole blood), toxicity, including cardiac safety, and efficacy of the 2 routes of administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosis of MM according to the SWOG criteria (annex I)
- •symptomatic MM stage II or III according to Durie-Salmon staging system (annex II) or stage I with one symptomatic osteolytic lesion
- •with progressive disease after at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation
- •with measurable levels of paraprotein in the serum (> 1g/dl) or in the urine (> 0.2g/24h)
- •age < 75 years
- •able to understand and to given an informed consent
- •male, female without childbearing potential or negative urine pregnancy test within 72 hours prior to beginning the treatment. Women of childbearing potential must be following adequate contraceptive measures. Men must agree to use an acceptable method of contraception (for themselves or female partners) for the duration of the study
- •no active systemic infection. In the presence of any active systemic infection, adequate broad-spectrum or organism-specific antibiotic coverage must be administered. Patients must be afebrile with stable vital signs while receiving antibiotics for at least 48 hours prior to beginning the treatment with Bortezomib.
- •Each subject will weigh ³50 kg and have a body mass index (BMI) of £30 kg/m2 (see annex V for BMI formula).
排除标准
- •life expectancy < 2 months
- •ECOG performance status > 2 (annex III)
- •proven amyloidosis
- •positive HIV serology
- •antecedents of severe psychiatric disease
- •> NCI grade 2 peripheral neuropathy (Annex IV)
- •History of clinically relevant cardiac disease, including prior myocardial infarction, prior or existing heart failure, existing uncontrolled angina or clinically significant pericardial disease Evidence of arrhythmia, 2nd degree or greater AV block or prolonged QTc interval (>0.45 seconds in males, >0.47 seconds in females) on screening ECG
- •serum biochemical values as follow
- •creatinine level > 200mmol/l
- •bilirubin, transaminases or gGT > 3 the upper normal limit
- •potassium, calcium or magnesium outside of upper or lower normal limits
- •haematology values as follow
- •platelet < 70x 109 /L within 14 days of enrollment
- •absolute neutrophil count <1.0 x 109/L within 14 days of enrolment
- •concomitant use of drugs able to modify QTc interval within 1 week prior to the first dose of bortezomib and during Cycle 1 (Annex VI)
- •concomitant use of potent inhibitors or inducers of the cytochrome P450 (CYP) enzymes 3A and 2C19 within 1 week prior to the first dose of bortezomib and during Cycle 1 (see annex VII list of representative drugs).
- •use of any experimental drugs within 30 days of baseline
- •hypersensitivity to bortezomib, boron, or mannitol
结局指标
主要结局
characterize the pharmacokinetics of the 2 routes of administration.
次要结局
- characterize the pharmacodynamics (20S proteasome inhibition in whole blood),
- toxicity, including cardiac safety,
- efficacy of the 2 routes of administration.
研究者
研究点 (6)
Loading locations...
相似试验
终止
2 期
Treatment Optimization in Patients With Untreated Multiple MyelomaMultiple MyelomaNCT02145598Dr. med. Lars-Olof Muegge85
已完成
1 期
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaOvarian Brenner TumorOvarian Clear Cell AdenocarcinomaOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous AdenocarcinomaOvarian Mucinous CystadenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous AdenocarcinomaOvarian Serous CystadenocarcinomaOvarian Transitional Cell CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaUndifferentiated Fallopian Tube CarcinomaUndifferentiated Ovarian CarcinomaNCT01074411National Cancer Institute (NCI)33
已完成
1 期
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaLymphomaLeukemiaNCT00963274Virginia Commonwealth University18
进行中（未招募）
1 期
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH TrialRecurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaNCT05514990University of Southern California10
进行中（未招募）
1 期
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT01861314National Cancer Institute (NCI)15